|
March 11, 2019 |
Davis Polk Advises ShockWave Medical, Inc. on Its $111.4 Million Initial Public Offering
|
|
|
March 11, 2019 |
Horizon Pharma Follow-On Offering
|
|
|
March 7, 2019 |
Medtronic Global Holdings S.C.A. €7 Billion Notes Offering
|
|
|
March 7, 2019 |
Merck $5 Billion Notes Offering
|
|
|
February 27, 2019 |
Davis Polk Advises CStone Pharmaceuticals on Its HK$2.24 Billion (US$285.05 Million) Initial Public Offering
|
|
|
February 25, 2019 |
Davis Polk Advises Roche on Its Acquisition of Spark Therapeutics
|
|
|
February 22, 2019 |
Pernix Enters into an Agreement for the Sale of Substantially All of Its Assets Subject to a Competitive Bidding Process and Files for Chapter 11
|
|
|
February 22, 2019 |
Sienna Biopharmaceuticals, Inc. $20 Million Common Stock Offering
|
|
|
February 22, 2019 |
Eli Lilly $4.5 Billion Notes Offering
|
|
|
February 11, 2019 |
Alector, Inc. Initial Public Offering
|
|
|
February 8, 2019 |
Aeglea BioTherapeutics, Inc. Common Stock and Pre-Funded Warrants Offering
|
|
|
January 22, 2019 |
Revance Therapeutics, Inc. $115 Million Common Stock Offering
|
|
|
January 18, 2019 |
Stemline Therapeutics, Inc. Common Stock Offering
|
|
|
January 17, 2019 |
Alnylam Pharmaceuticals, Inc. $387.5 Million Common Stock Offering
|
|
|
January 15, 2019 |
Davis Polk Wins Six Practice Group of the Year Awards from Law360
|
|
|
January 9, 2019 |
Alan Denenberg Quoted in WSJ on Stalled IPO Market
|
|
|
January 9, 2019 |
Alan Denenberg Appears on CNBC to Discuss Impact of Government Shutdown on IPOs
|
|
|
January 3, 2019 |
Bristol-Myers Squibb Acquires Celgene
|
|
|
December 17, 2018 |
Hologic, Inc. $3 Billion Senior Secured Credit Facilities Refinancing
|
|
|
December 14, 2018 |
Secondary Offering of NeoGenomics, Inc. Common Stock
|
|
|
December 11, 2018 |
Davis Polk Advises Notre Dame Intermédica on Its R$2.7 Billion Equity Offering
|
|
|
December 10, 2018 |
Davis Polk Advises Nutrisystem on Its Acquisition by Tivity Health
|
|
|
December 6, 2018 |
Davis Polk Advises Mereo BioPharma Group plc on Its Combination with OncoMed Pharmaceuticals, Inc.
|
|
|
November 30, 2018 |
DexCom, Inc. $850 Million Convertible Notes Offering
|
|
|
November 27, 2018 |
Taiwan Liposome Company, Ltd. Initial Public Offering
|
|
|
November 2, 2018 |
Orchard Therapeutics plc Initial Public Offering
|
|
|
October 31, 2018 |
Innovent Biologics, Inc. HK$3.15 Billion (US$403.1 Million) Initial Public Offering
|
|
|
October 31, 2018 |
Davis Polk Advises Novo Nordisk on Its Acquisition of U.S. and Canadian Rights to Macrilen from Strongbridge Biopharma
|
|
|
October 30, 2018 |
Gamida Cell Ltd. $50 Million Initial Public Offering
|
|
|
October 16, 2018 |
Davis Polk Advises Laboratorios Farmacéuticos Rovi, S.A. on Its €80 Million Follow-On Offering
|
|
|
October 11, 2018 |
Davis Polk Advises Aetna on the U.S. Department of Justice Approval of Its Acquisition by CVS Health
|
|
|
October 10, 2018 |
AtriCure, Inc. Common Stock Offering
|
|
|
October 9, 2018 |
Kodiak Sciences Inc. Initial Public Offering
|
|
|
October 5, 2018 |
Kala Pharmaceuticals, Inc. Common Stock Offering
|
|
|
September 27, 2018 |
Cipla Quality Chemical Industries Limited Initial Public Offering and USE Listing
|
|
|
September 24, 2018 |
Davis Polk Advises Shire on Its $2.325 Billion Concurrent Tender Offers
|
|
|
September 18, 2018 |
AbbVie Inc. $6 Billion Senior Notes Offering
|
|
|
September 18, 2018 |
Galapagos NV €296.2 Million Follow-On Offering of American Depositary Shares
|
|
|
September 17, 2018 |
Davis Polk Advises Roche Holdings on Its $1.4 Billion Notes Offering
|
|
|
September 17, 2018 |
Halfmoon Parent, Inc. $20 Billion Senior Notes Offering
|
|
|
September 10, 2018 |
Zai Lab Limited $150 Million Follow-On Offering of American Depositary Shares
|
|
|
August 30, 2018 |
Walgreens Boots Alliance $3.5 Billion Revolving Credit Facility
|
|
|
August 21, 2018 |
Illumina, Inc. $750 Million Convertible Senior Notes Offering
|
|
|
August 20, 2018 |
Zoetis Inc. $1.5 Billion Senior Notes Offering
|
|
|
August 17, 2018 |
Davis Polk Advises ViewRay, Inc. on Its $172.5 Million Follow-On Common Stock Offering
|
|
|
August 17, 2018 |
Davis Polk Advises AstraZeneca on Its $3 Billion SEC-Registered Notes Offering
|
|
|
August 14, 2018 |
REGENXBIO Inc. $175.5 Million Common Stock Offering
|
|
|
August 14, 2018 |
NeoGenomics Follow-On Offering
|
|
|
August 9, 2018 |
BeiGene Ltd. HK$7.08 Billion (US$903 Million) Public Offering on the Hong Kong Stock Exchange
|
|
|
August 2, 2018 |
Davis Polk Advises Pernix on Private Exchange Offers
|
|
|
August 1, 2018 |
Davis Polk Advises AC Immune SA on Its $117.5 Million Follow-On Public Offering and Subscription Rights Offerings
|
|
|
July 27, 2018 |
Teladoc, Inc. $348.9 Million Common Stock Offering
|
|
|
July 26, 2018 |
Constellation Pharmaceuticals Initial Public Offering
|
|
|
July 23, 2018 |
Allakos Inc. Initial Public Offering
|
|
|
July 18, 2018 |
Davis Polk Advises Auris Medical Holding AG on Its Offering of Common Shares and Warrants
|
|
|
July 17, 2018 |
CytomX Therapeutics, Inc. Follow-On Offering
|
|
|
July 16, 2018 |
Natera, Inc. $103.5 Million Follow-On Public Offering
|
|
|
July 2, 2018 |
Forty Seven, Inc. $112.6 Million Initial Public Offering
|
|
|
July 2, 2018 |
Davis Polk Advises Entera Bio Ltd. on Its Initial Public Offering
|
|
|
June 26, 2018 |
Magenta Therapeutics, Inc. Initial Public Offering
|
|
|
June 25, 2018 |
Aptinyx Inc. Initial Public Offering
|
|
|
June 19, 2018 |
Davis Polk Advises Roche on Its Acquisition of Foundation Medicine
|
|
|
June 14, 2018 |
Davis Polk Advises Kadmon Holdings, Inc. on Its Follow-on Offering of Common Stock
|
|
|
June 11, 2018 |
Deciphera Pharmaceuticals Follow-On Offering
|
|
|
June 4, 2018 |
Davis Polk Advises Valeant Pharmaceuticals International, Inc. on Its $2.05 Billion Refinancing
|
|
|
June 1, 2018 |
Valeant Pharmaceuticals International $4.565 Billion Term Loan Facility and $1.225 Billion Revolving Credit Facility
|
|
|
May 30, 2018 |
Iterum Therapeutics plc Initial Public Offering
|
|
|
May 29, 2018 |
Melinta Therapeutics, Inc. Common Stock Offering
|
|
|
May 25, 2018 |
Coherus BioSciences, Inc. $86.25 Million Follow-On Offering
|
|
|
May 25, 2018 |
Ardelyx, Inc. $50 Million Public Offering
|
|
|
May 22, 2018 |
Calyxt, Inc. Common Stock Offering
|
|
|
May 22, 2018 |
AbbVie Inc. $3 Billion 364-Day Term Loan Credit Facility
|
|
|
May 9, 2018 |
Davis Polk Advises Shire on Its Proposed Acquisition by Takeda
|
|
|
May 9, 2018 |
Davis Polk Advises We Doctor Holdings Limited on Its $500 Million Issuance of Shares
|
|
|
May 8, 2018 |
ASLAN Pharmaceuticals Initial Public Offering and NASDAQ Listing
|
|
|
May 7, 2018 |
Unity Biotechnology, Inc. $85 Million Initial Public Offering
|
|
|
May 4, 2018 |
Ping An Healthcare and Technology Company Limited HK$8.77 Billion ($1.12 Billion) Initial Public Offering
|
|
|
April 25, 2018 |
Davis Polk Advises McKesson on Its Acquisition of Medical Specialties Distributors
|
|
|
April 25, 2018 |
Davis Polk Advises Notre Dame Intermédica on Its R$2.4 Billion Initial Public Offering
|
|
|
April 23, 2018 |
Aeglea BioTherapeutics $36 Million Common Stock Offering
|
|
|
April 16, 2018 |
Davis Polk Advises Shire on the Sale of Its Oncology Business to Servier
|
|
|
April 10, 2018 |
Cellectis S.A. Follow-On Offering
|
|
|
April 4, 2018 |
PTC Therapeutics, Inc. Common Stock Offering
|
|
|
April 3, 2018 |
Davis Polk Advises iKang Healthcare on Its Acquisition by Yunfeng Capital and Alibaba
|
|
|
April 3, 2018 |
Davis Polk Advises Charles River Laboratories International, Inc. on Its $500 Million Notes Offering
|
|
|
March 27, 2018 |
Accelerate Diagnostics, Inc. $150 Million Convertible Senior Notes Offering
|
|
|
March 26, 2018 |
Davis Polk Advises Valeant Pharmaceuticals International, Inc. on Its $1.5 Billion Refinancing
|
|
|
March 23, 2018 |
Xencor, Inc. Follow-On Offering
|
|
|
March 12, 2018 |
Corvus Pharmaceuticals, Inc. Common Stock Offering
|
|
|
March 8, 2018 |
Davis Polk Advises Agilent Technologies on Its Acquisition of Advanced Analytical Technologies
|
|
|
March 5, 2018 |
Atara Biotherapeutics, Inc. Follow-On Offerings
|
|
|
March 2, 2018 |
Anthem, Inc. $2.1 Billion Senior Notes Offering and Remarketing of Subordinated Notes
|
|
|
February 26, 2018 |
Davis Polk Advises ViewRay, Inc. on Its $59 Million Direct-Registered Equity Offering
|
|
|
February 26, 2018 |
Aimmune Therapeutics Common Stock Offering
|
|
|
February 20, 2018 |
Celgene $4.5 Billion Notes Offering
|
|
|
February 16, 2018 |
Avadel Pharmaceuticals $143.7 Million Exchangeable Senior Notes Offering
|
|
|
February 15, 2018 |
Davis Polk Advises Affimed on Its $26.5 Million Offering of Shares
|
|
|
February 15, 2018 |
Davis Polk Advises Roche on Its Acquisition of Flatiron Health
|
|
|
February 13, 2018 |
Davis Polk Advises Charles River on Its Acquisition of MPI Research
|
|
|
February 5, 2018 |
Seattle Genetics, Inc. $600 Million Equity Offering
|
|
|
February 1, 2018 |
Oliver Smith Profiled in The Deal
|
|
|
January 31, 2018 |
Varian Medical Systems Acquires Sirtex Medical
|
|
|
January 30, 2018 |
Solid Biosciences Inc. Initial Public Offering
|
|
|
January 29, 2018 |
ConforMIS, Inc. Common Stock Offering
|
|
|
January 29, 2018 |
Five Prime Therapeutics, Inc. Common Stock Offering
|
|
|
January 26, 2018 |
Adamas Pharmaceuticals, Inc. Common Stock Follow-On Offering
|
|
|
January 26, 2018 |
Stemline Therapeutics, Inc. Common Stock Offering
|
|
|
January 23, 2018 |
Agios Pharmaceuticals, Inc. Common Stock Offering
|
|
|
January 19, 2018 |
Hologic, Inc. $1 Billion Senior Notes Offering
|
|
|
January 5, 2018 |
Davis Polk Advises TiGenix on Its Acquisition by Takeda
|
|
|
December 12, 2017 |
Denali Therapeutics Inc. Initial Public Offering
|
|
|
December 11, 2017 |
Revance Therapeutics, Inc. $190 Million Common Stock Offering
|
|
|
December 8, 2017 |
Editas Medicine, Inc. $50 Million Follow-On Offering
|
|
|
December 4, 2017 |
Davis Polk Advises Aetna on Its Acquisition by CVS Health
|
|
|
November 30, 2017 |
Anthem, Inc. Cash Tender Offers
|
|
|
November 21, 2017 |
Anthem, Inc. $5.5 Billion Senior Notes Offering
|
|
|
November 16, 2017 |
Davis Polk Advises Roche on Its €250 Million Cash Tender Offer
|
|
|
November 16, 2017 |
Alnylam Pharmaceuticals, Inc. $805 Million Common Stock Offering
|
|
|
November 10, 2017 |
Davis Polk Advises InflaRx N.V. on Its Initial Public Offering
|
|
|
November 10, 2017 |
Insulet Corporation Convertible Senior Notes Offering
|
|
|
November 9, 2017 |
Celgene $3 Billion Notes Offering
|
|
|
November 7, 2017 |
Davis Polk Advises McKesson Corporation on Its Acquisition of RxCrossroads from CVS Health Corporation
|
|
|
November 6, 2017 |
Allena Pharmaceuticals Initial Public Offering
|
|
|
November 6, 2017 |
Omnicell, Inc. $125 Million SEC-Registered At-The-Market Offering
|
|
|
October 30, 2017 |
Davis Polk Advises Advanced Accelerator Applications on Its Acquisition by Novartis
|
|
|
October 30, 2017 |
Ablynx NV $230 Million U.S. Initial Public Offering of ADSs and Listing on the NASDAQ
|
|
|
October 25, 2017 |
Davis Polk Advises ViewRay, Inc. on a $50 Million Direct Registered Equity Offering
|
|
|
October 20, 2017 |
Davis Polk Advises Auris Medical Holding AG on Its Registered Offering of Common Shares and Equity Line of Financing
|
|
|
October 16, 2017 |
Flexion Therapeutics, Inc. $122.4 Million Follow-On Offering
|
|
|
October 12, 2017 |
Davis Polk Advises China Biologic Products on Its Acquisition of Tianxinfu
|
|
|
October 10, 2017 |
Hologic, Inc. $350 Million Senior Notes Offering
|
|
|
September 29, 2017 |
Deciphera Pharmaceuticals Initial Public Offering
|
|
|
September 28, 2017 |
Davis Polk Advises Kadmon Holdings, Inc. on Its Follow-on Offerings of Common Stock and Warrants to Purchase Common Stock
|
|
|
September 26, 2017 |
Juno Therapeutics, Inc. $288 Million Follow-On Offering
|
|
|
September 22, 2017 |
Zai Lab Limited Initial Public Offering and NASDAQ Listing
|
|
|
September 22, 2017 |
Magellan Health, Inc. $400 Million Senior Notes Offering
|
|
|
September 19, 2017 |
Healthcare Trust of America, Inc. $500 Million At-the-Market Offering
|
|
|
September 15, 2017 |
Portola Pharmaceuticals Follow-On Offering
|
|
|
September 12, 2017 |
Zoetis Inc. $1.25 Billion Senior Notes Offering
|
|
|
August 23, 2017 |
Jazz Pharmaceuticals $500 Million Exchangeable Senior Notes Offering
|
|
|
August 18, 2017 |
Oxford Immunotec Global PLC Offering of Ordinary Shares
|
|
|
August 16, 2017 |
BeiGene, Ltd. Public Offering
|
|
|
August 10, 2017 |
Celgene $500 Million Notes Offering
|
|
|
August 10, 2017 |
Spark Therapeutics Follow-On Offering
|
|
|
August 7, 2017 |
Davis Polk Advises Accuray Incorporated on Its Private Exchange Offer
|
|
|
August 2, 2017 |
Davis Polk Advises PharMerica on Its Acquisition by KKR and Walgreens
|
|
|
August 2, 2017 |
$3.1 Billion Financing for inVentiv’s Merger with INC Research
|
|
|
August 2, 2017 |
Davis Polk Advises AstraZeneca as Special Tax Counsel on Its Strategic Collaboration with Merck
|
|
|
August 1, 2017 |
China Biologic Products Redomicile from Delaware to the Cayman Islands
|
|
|
August 1, 2017 |
Sienna Biopharmaceuticals Initial Public Offering
|
|
|
July 31, 2017 |
LabCorp Acquires Chiltern
|
|
|
July 28, 2017 |
Biotoscana Investments $377.7 Million Initial Public Offering
|
|
|
July 26, 2017 |
Davis Polk Advises Pernix Therapeutics Holdings, Inc. on Its Refinancing Transactions
|
|
|
July 25, 2017 |
Kala Pharmaceuticals, Inc. Initial Public Offering
|
|
|
July 24, 2017 |
Davis Polk Advises Mitsubishi Tanabe Pharma on Its Acquisition of NeuroDerm
|
|
|
July 19, 2017 |
Akcea Therapeutics Initial Public Offering
|
|
|
July 5, 2017 |
Dova Pharmaceuticals, Inc. Initial Public Offering
|
|
|
July 5, 2017 |
Mersana Therapeutics, Inc. Initial Public Offering
|
|
|
June 28, 2017 |
Royal Philips Acquires Spectranetics
|
|
|
June 28, 2017 |
Evolent Health, Inc. Common Stock Secondary Offering
|
|
|
June 27, 2017 |
Teladoc, Inc. $275 Million Convertible Senior Notes Offering
|
|
|
June 23, 2017 |
Bristol-Myers Squibb Company Debt Tender Offer
|
|
|
June 20, 2017 |
Loxo Oncology, Inc. Common Stock Offering
|
|
|
June 12, 2017 |
Davis Polk Advises AstraZeneca on Its $2 Billion SEC-Registered Notes Offering
|
|
|
June 12, 2017 |
Cardinal Health $5.2 Billion Notes Offering
|
|
|
June 7, 2017 |
NanoString Technology Public Stock Offering
|
|
|
May 31, 2017 |
Achaogen Common Stock Offering
|
|
|
May 30, 2017 |
Alnylam Pharmaceuticals, Inc. Common Stock Offering
|
|
|
May 19, 2017 |
Evolent Health, Inc. Common Stock Secondary Offering
|
|
|
May 12, 2017 |
DexCom, Inc. $350 Million Convertible Notes Offering
|
|
|
May 11, 2017 |
AMAG Pharmaceuticals, Inc. $300 Million Convertible Senior Notes Offering
|
|
|
May 9, 2017 |
Eli Lilly $2.25 Billion Notes Offering
|
|
|
May 2, 2017 |
Flexion Therapeutics $201.25 Million Convertible Senior Notes Offering
|
|
|
April 24, 2017 |
Agios Pharmaceuticals, Inc. Common Stock Offering
|
|
|
April 21, 2017 |
Galapagos NV €363.9 Million Follow-On Offering of American Depositary Shares
|
|
|
April 18, 2017 |
$4.5 Billion Bridge Facility for Cardinal Health, Inc.’s Acquisition of Stock and Assets from Medtronic plc
|
|
|
April 14, 2017 |
Abbott and Alere Amend Merger Agreement
|
|
|
March 31, 2017 |
Evolent Health Common Stock Secondary Offering
|
|
|
March 28, 2017 |
Medtronic $2 Billion Notes Offering
|
|
|
January 19, 2017 |
Davis Polk Successfully Represents Aetna in Patent Infringement Suit
|
|
|
June 26, 2009 |
Second Circuit Affirms Dismissal of Securities Class Action Against AstraZeneca
|
|
|
February 2, 2009 |
Shareholder Plaintiff's Fee Petition in Roche-Ventana Merger Denied
|
|
|
July 25, 2008 |
AstraZeneca Wins Before California State Court of Appeals
|
|
